To explore the association between the predictive capacity of the CD3+/CD4+ cell–myosteatosis in gastric cancer patients and the pTNM stage, we categorized 124 patients into an early pTNM stage (0/Tis + I + II) group and 66 patients into an advanced pTNM stage (III + IV) group. Here, CD4 is linked to gastric cancer.